Changing the face of cancer one patient at a time by enhancing the visualization and precision of cancer surgery, giving patients a chance at a longer and better quality of life.
NX Development Corp. (NXDC) is a life sciences company based in Lexington, KY dedicated to the development of ALA HCl for tumor visualization.
NXDC is a wholly-owned subsidiary of photonamic GmbH & Co. KG in Pinneberg, Germany (PHN). PHN is the licensor of GleolanTM (aminolevulinic acid HCl [ALA HCl]) to NXDC. The companies share an eight-year working relationship and are wholly-owned by SBI Holdings Inc. in Tokyo, Japan.
Alan Ezrin, Ph.D.
Co-Founder, President and
Previous co-founder of Cardiome Pharma and ConjuChem, both of which matured from start-up stage to multi-hundred million dollar market cap firms under his scientific and business leadership.
Dr. Ezrin 35+ years of experience in research and business development in both the pharmaceutical/biotechnology sectors in the US & Canada. He holds a Ph.D. in pharmacology from the University of Miami, and serves on the Board of NX PharmaGen and on the Board of Advisors for the Preston Robert Tisch Brain Tumor Center at Duke University.
Chief Operating Officer and
Chief Financial Officer
35+ years’ experience as a financial executive. Certified Public Accountant, Certified Forensic Consultant and a Fellow at the American College of Forensic Examiners. Former manager at the Big 4 Accounting Firm of Deloitte Former Managing Partner of the accounting firm of Cooper and Cobb, CPAs. Former CFO of the publicly traded company Spinnaker Software. Consulted to numerous Companies at their start including iRobot, Northern Light Technologies and Palm Technologies. Graduated with high honors from Northeastern University with a BS in Accounting.